Health Care • Medical/Dental Instruments
$86.24 ▼ -7.15
(-7.66%)
MKT CAP: $5.17B • VOL: 1.80M
52W L $60 52W H $95
MMSI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.52B | $1.36B | $1.26B |
| YoY Revenue Growth % | +11.8% | +7.9% | — |
| Gross Profit | $738.3M | $643.3M | — |
| Gross Margin % | 48.7% | 47.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $184.7M | $155.7M | $123.9M |
| Operating Margin % | 12.2% | 11.5% | 9.9% |
| Net Income (GAAP) | $128.5M | $120.4M | $94.4M |
| EBITDA (Normalized) | $250.1M | $183.8M | $169.2M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $297.4M | $220.8M | $145.2M |
| Capital Expenditures (CapEx) | $81.7M | $35.1M | $56.6M |
| Free Cash Flow (FCF) | $215.7M | $185.7M | $88.6M |
| FCF Margin % | 14.2% | 13.7% | 7.0% |
| Return on Invested Capital (ROIC %) | 7.8% | 7.1% | 5.3% |
| Cash & Short-Term Equivalents | $446.4M | $376.7M | — |
| Total Debt (Short + Long Term) | $734.0M | $729.6M | $717.7M |
| Total Stockholders' Equity | $1.58B | $1.38B | $1.47B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MMSI.